RxDoctor Payments Data

Ara Maranian, MD

Cardiovascular Disease · Manassas, VANPI 1821076142

Payments from drug & device makers

$365in general payments, 2019–2025

Across 19 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$97
  • Edwards Lifesciences$89
  • Abbott$49
  • E.r. Squibb & Sons, L.L.C.$39
  • Pfizer$25
  • Johnson & Johnson$24
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$365 in reported general payments places this provider in the 20th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$399,860
Medicare patients
2,317
Services billed
6,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban474$632,327
XareltoRivaroxaban296$344,958
EntrestoSacubitril/Valsartan38$61,989
Repatha SureclickEvolocumab44$49,466
JardianceEmpagliflozin22$27,034
Dabigatran EtexilateDabigatran Etexilate Mesylate64$19,471
FarxigaDapagliflozin Propanediol19$16,124
Metoprolol Succinate540$9,025
NexlizetBempedoic Acid/Ezetimibe13$8,163
Dofetilide16$7,001
Amiodarone Hcl83$4,772
Atorvastatin Calcium407$3,806
Diltiazem 24hr Er (Cd)Diltiazem Hcl88$3,545
Bumetanide68$3,150
Ranolazine ErRanolazine38$2,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$632,327474 claims
Johnson & JohnsonXarelto$24$344,958296 claims
NovartisEntresto$97$61,98938 claims
AstraZenecaFarxiga$23$16,12419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →